Yiheng Capital Management’s Denali Therapeutics DNLI Stock Holding History

Yiheng Capital Management’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-469,981	Closed	-$6.82M	–	28
2025 Q3	$6.82M	Hold	469,981	–	–	1.01%	16
2025 Q2	$6.58M	Hold	469,981	–	–	0.59%	16
2025 Q1	$6.39M	Sell	469,981 -230,117	-33%	-$4.41M	0.59%	15
2024 Q4	$14.3M	Buy	700,098 +100,000	+17%	+$2.56M	0.55%	15
2024 Q3	$17.5M	Sell	600,098 -550,586	-48%	-$13.6M	0.9%	13
2024 Q2	$26.7M	Hold	1,150,684	–	–	2.15%	14
2024 Q1	$23.6M	Hold	1,150,684	–	–	1.31%	13
2023 Q4	$24.7M	Hold	1,150,684	–	–	1.42%	13
2023 Q3	$23.7M	Hold	1,150,684	–	–	1.21%	16
2023 Q2	$34M	Buy	1,150,684 +136,000	+13%	+$3.82M	1.84%	15
2023 Q1	$23.4M	Hold	1,014,684	–	–	0.92%	19
2022 Q4	$28.2M	Hold	1,014,684	–	–	1.25%	16
2022 Q3	$31.1M	Hold	1,014,684	–	–	1.92%	14
2022 Q2	$29.9M	Hold	1,014,684	–	–	1.71%	19
2022 Q1	$32.6M	Buy	1,014,684 +679,500	+203%	+$23.4M	1.49%	20
2021 Q4	$14.9M	Buy	+335,184	New	+$15.9M	0.76%	23

Other funds holding DNLI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Yiheng Capital Management's DNLI Position: Q4 2025 in Review

Yiheng Capital Management sold out of Denali Therapeutics (DNLI) in Q4 2025, closing a stake of 469,981 shares — an estimated $6.82M sold.

Yiheng Capital Management first reported a position in DNLI in Q4 2021 and held it in 16 quarters. The position peaked at $34M in Q2 2023. 250 funds tracked by Wall St. Rank hold DNLI as of Q4 2025.

Yiheng Capital Management reported no remaining Denali Therapeutics position as of Q4 2025 after selling out during the quarter.
Yiheng Capital Management sold 469,981 Denali Therapeutics shares in Q4 2025, an estimated $6.82M.
Yiheng Capital Management first reported a position in Denali Therapeutics in Q4 2021 and held it in 16 quarters.
Yiheng Capital Management's Denali Therapeutics position peaked at $34M in Q2 2023.
250 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2025.

Based on Yiheng Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.